DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 14:10:41 05/06/2024 BST | ||
| 270.59 EUR / 271.96 EUR | +0.23% |
|
| Current month | -0.05% | ||
| 1 month | +0.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 271 | +0.14% |
| 04/06/24 | 270.6 | +0.02% |
| 03/06/24 | 270.6 | -0.07% |
| 31/05/24 | 270.8 | +0.07% |
| 30/05/24 | 270.6 | -0.22% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 12:21 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8M |
| ISIN | DE000ME7D8M9 |
| Date issued | 23/01/2024 |
| Maturity | 20/12/2024 (198 Days) |
| Parity | 1 : 1 |
| Emission price | 263.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 271.9 € |
|---|---|
| Lowest since issue | 258.8 € |
| Spread | 1.37 € |
| Spread % | 0.50% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat